Organon Returns Ebopiprant to XOMA
27 oct. 2023 17h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
XOMA Declares Quarterly Preferred Stock Dividends
25 sept. 2023 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA Declares Quarterly Preferred Stock Dividends
20 juin 2023 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA Declares Quarterly Preferred Stock Dividends
22 déc. 2022 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
22 nov. 2022 07h00 HE
|
ObsEva SA
Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to...
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
22 nov. 2022 01h00 HE
|
ObsEva SA
Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to...
XOMA Declares Quarterly Preferred Stock Dividends
21 sept. 2022 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends...
XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program
03 mai 2021 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc....
XOMA’s Royalty Portfolio Grows with Addition of Three Royalty Assets
15 avr. 2021 09h05 HE
|
XOMA Corporation
EMERYVILLE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced its portfolio of potential future milestone and royalty assets has increased with the addition...